Clinical Trial: Prizma Pulse Oximeter Evaluation

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Prizma Pulse Oximeter Evaluation

Brief Summary:

This study is intended to evaluate performance of the new design sufficiently to support performance claims for an FDA 510K submission or ISO technical file. Specifically:

  • SpO2 value range 70% to 100%
  • 10 or more subjects, at least 3 of dark pigmentation
  • At least 200 data points
  • Meeting the following test required by the 2013 FDA Guidance on Pulse Oximeters - Premarket Notification Submissions and by ISO 80601-2-61 on Pulse Oximeters:

  • 2013 FDA Guidance on Pulse Oximeters - Premarket Notification Submissions:

    • 4.1. ACCURACY OF PULSE OXIMETERS
    • 4.1.1 IN VIVO TESTING FOR SPO2 ACCURACY UNDER LABORATORY CONDITIONS

  • ISO 80601-2-61:2011 Annex EE.2 and clause 201.12.1.101.2

    • 201.12.1.101 SpO2 accuracy of pulse oximeter equipment
    • 201.12.1.101.2 Determination of SpO2 accuracy

Detailed Summary:

The device under test was the Prizma which is a phone cover biometric device that includes reflectance oximetry. This device is a spot checker that requires the patient to hold their finger on the sensor during the measurement. The subjects were asked not to move during the study. In order to get consistent measurements the fingers were taped to the test device. The tape acted mainly as a reminder, and there were some problems with finger movement. A radial arterial cannula was placed in either the left or right wrist of each subject.

Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1). Each subject had control data taken at the beginning of each experiment, with two control blood samples drawn while breathing room air. Hypoxia was induced to different levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, room air, and carbon dioxide. Oxyhemoglobin saturation was reduced to a series of targets and stabilized at the plateau value. Each plateau level of oxyhemoglobin saturation was maintained for at least 30 seconds. Two arterial blood samples were then obtained, approximately 30 seconds apart. A total of 24 samples were obtained per subject. Data were recorded by Bickler-Ye lab and provided for analysis.


Sponsor: G Medical Innovations Ltd.

Current Primary Outcome: Blood oxygen saturation [ Time Frame: 2 days ]

Comparison of Measurements: Prizma Device versus Gold Standard


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: G Medical Innovations Ltd.

Dates:
Date Received: February 27, 2017
Date Started: April 15, 2016
Date Completion:
Last Updated: March 9, 2017
Last Verified: March 2017